Organisation paid for research Program year 2025 Source: CMS Open Payments

Childrens Specialty Group PLLC

Neither a doctor nor a teaching hospital

Research payments

$825,289

198 payments

Through program year 2025, Childrens Specialty Group PLLC is reported as receiving $825,289 in research payments, across 198 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $313,501 51
2024 Research $49,308 27
2023 Research $115,267 38
2022 Research $54,003 30
2021 Research $103,660 24
2020 Research $100,832 19
2019 Research $88,719 9

Breakdown

Who paid Research payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $214,741 42 payments
  2. Sarepta Therapeutics, Inc. $120,830 10 payments
  3. Eli Lilly and Company $103,502 23 payments
  4. Vertex Pharmaceuticals Incorporated $101,571 7 payments
  5. Pfizer Inc. $61,291 13 payments
  6. Genentech, Inc. $58,679 5 payments
  7. PTC Therapeutics, Inc. $52,829 51 payments
  8. AveXis $36,690 18 payments
  9. Astellas Pharma Inc $22,296 4 payments
  10. H. Lundbeck A S $22,034 8 payments
Studies the money was for Research payments · program years 2019–2025
  1. TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy $119,907 15 payments
  2. 4045-301 $114,030 5 payments
  3. A Phase 1/2, Randomized, Double-blind, Placebo?controlled Single- and Multiple?dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX?670 in Adult Subjects with Myotonic Dystrophy Type 1 $45,474 1 payment
  4. An Open-Label, Safety Study for Ataluren (Ptc124) Patients With Nonsense Mutation Dystrophinopathy $43,529 45 payments
  5. A Phase II Study of Satralizumab in Pediatric Patients With Duchenne Muscular Dystrophy $41,804 4 payments
  6. Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis $37,021 5 payments
  7. A Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy $36,690 18 payments
  8. A Phase 3 Multicenter Randomized Doubleblind Placebo Controlled Study to Evaluate the Safety and Efficacy of PF 06939926 for the Treatment of Duchenne Muscular Dystrophy $33,205 5 payments
  9. A Long-term Extension Study to Evaluate the Safety and Tolerability of TAK-861 in Participants With Selected Central Hypersomnia Conditions $32,412 8 payments
  10. A Master Protocol for A Phase 3 Multicenter Open-Label Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Children and Adolescents With Moderate-To-Severe Ulcerative Colitis Or Crohn's Disease $32,082 2 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $88,638 10 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record